Monoglyerides (MGs) are short-lived, intermediary lipids deriving from the degradation of phospho-and neutral lipids, and monoglyceride lipase (MGL), also designated as monoacylglycerol lipase (MAGL), is the major enzyme catalyzing the hydrolysis of MGs into glycerol and fatty acids. This distinct function enables MGL to regulate a number of physiological and pathophysiological processes since both MGs and fatty acids can act as signaling lipids or precursors thereof. The most prominent MG species acting as signaling lipid is 2-arachidonoyl glycerol (2-AG) which is the most abundant endogenous agonist of cannabinoid receptors in the body. Importantly, recent observations demonstrate that 2-AG represents a quantitatively important source for arachidonic acid, the precursor of prostaglandins and other inflammatory mediators. Accordingly, MGL-mediated 2-AG degradation affects lipid signaling by cannabinoid receptor-dependent and independent mechanisms. Recent genetic and pharmacological studies gave important insights into MGL's role in (patho-)physiological processes, and the enzyme is now considered as a promising drug target for a number of disorders including cancer, neurodegenerative and inflammatory diseases. This review summarizes the basics of MG (2-AG) metabolism and provides an overview on the therapeutic potential of MGL.
1. Introduction
Milestones in monoglyceride lipase research
Early work from the 1960s suggested the presence of a distinct enzymatic activity that hydrolyzes monoglycerides (MGs) to glycerol and fatty acids in the intestine (Senior & Isselbacher, 1963) and in adipose tissue (Vaughan, Berger, & Steinberg, 1964) of rats. This activity was later ascribed to monoglyceride lipase [MGL, also known as monoacylglycerol lipase (MAGL)], a 33 kDa serine hydrolase that cleaves MGs at neutral pH (Kupiecki, 1966) . Subsequently, MGL was purified, cloned, and enzymatically characterized (Karlsson, Contreras, Hellman, Tornqvist, & Holm, 1997; Tornqvist & Belfrage, 1976) . The enzyme harbors an alpha/beta hydrolase fold and a catalytic triade with an active serine located within a GXSXG consensus sequence commonly found in lipases (Karlsson et al., 1997) . MGL returned into the spotlight of research when Dinh et al. demonstrated that it degrades 2-arachidonoyl glycerol (2-AG), the most abundant endocannabinoid (EC) in the body (Dinh et al., 2002) . This finding led to the development of powerful tools used today in MGL research, including selective MGL inhibitors (Table 1) and genectic mouse models of MGL deficiency or overexpression (Table 2) . Thereby, MGL was identified as the major enzyme providing arachidonic acid (AA) for eicosanoid synthesis in certain tissues (Nomura, Morrison, et al., 2011) . Furthermore, MGL's crystal stucture was solved unveiling how the enzyme interacts with membranes, substrates, and inhibitors (Bertrand et al., 2010; Labar, Bauvois, et al., 2010; Schalk-Hihi et al., 2011) . Genetic as well as pharmacological studies gave important insights into MGL's role in (patho-)physiological processes, and the enzyme is now considered as a promising therapeutic target for the treatment of a number of disorders including cancer, neurodegenerative and inflammatory diseases.
Overview on monoglyceride metabolism
MGs are short-lived lipids deriving from intra-and extracellular sources. The extracellular quantitatively most important source of MGs are triglyceride-(TG)-rich lipoproteins since lipoprotein lipase (LPL) hydrolyzes TGs in sn-1-and sn-3-position, generating 2-MG species (Goldberg & Merkel, 2001) . Similarly, digestion of dietary TG by pancreatic lipase results in the generation of 2-MG (Lowe, 1994) . Extracellularly generated MGs are internalized by cells and may be degraded by MGL (Fig. 1A) or re-esterified to TG by acyl-CoA:monoacylglycerol and acyl-CoA:diacylglycerol acyltransferase (MGAT and DGAT) reactions. The latter pathway is specifically important in the small intestine where MGAT enzymes synthesize about 80% of the TG incorporated into chylomicrons (reviewed in (Shi & Cheng, 2009) ). MGs can also derive from intracellular TGs stored in cytosolic lipid droplets (Fig. 1B) . These TGs are hydrolyzed by the sequential action of two lipases. The first and rate-limiting step is catalyzed by adipose triglyceride lipase (ATGL) generating diglycerides (DGs) and fatty acids. These DGs are then hydrolyzed by hormone-sensitive lipase (HSL), releasing another fatty acid and thereby generating MG (Schweiger et al., 2006) . Finally, MGL cleaves the last fatty acid off the MG and releases glycerol. Membrane bound glycerophospholipids are precursors for the generation of MGs (Fig. 1C, D) . Glycerophospholipids are hydrolyzed by phospholipase C (PLC) to generate DGs which are further metabolized by sn-1-specific DG lipases (DAGLα and DAGLβ) (Bisogno et al., 2003) to generate 2-MG (Bisogno, Melck, De Petrocellis, & Di Marzo, 1999; Stella, Schweitzer, & Piomelli, 1997) . This is the major pathway for the generation of the EC 2-AG. AA and other polyunsaturated fatty acids (PUFAs) are commonly found esterified in sn-2 position of glycerophospholipids and TGs. Accordingly, by degrading 2-MG from different sources, MGL can affect PUFA metabolism. It is currently unknown whether also 2-AG, deriving from TG of extra-or intracellular sources, can contribute to EC signaling. As summarized in Fig. 1 , the heterogeneity of MG sources correlates with the subcellular distribution of MGL. The enzyme has been shown to localize to plasma membranes, endoplasmic reticulum, and lipid droplets (Blankman, Simon, & Cravatt, 2007; Dinh et al., 2002; Sakurada & Noma, 1981; Tornqvist & Belfrage, 1976) . Upon over-expression of MGL in cells, it equally distributes between membrane and cytosolic fractions (Dinh et al., 2002) . However, brain tissue fractionation revealed that more than 90% of endogenous MGL activity is found in the membrane fraction (Blankman et al., 2007) .
Biochemical properties, tissue distribution, and regulation of MGL
MGL is capable of hydrolyzing MG species with different fatty acid chain length and saturation. The enzyme has no positional preference for sn-1(3) or 2-MGs, yet a slight preference for MG species containing unsaturated fatty acids (Ghafouri et al., 2004; Vandevoorde et al., 2005) . Recent data suggest that MGL also degrades prostaglandin glycerol esters which represent still poorly characterized inflammatory mediators (Savinainen et al., 2014) . Finally, MGL has been implicated in non-oxidative ethanol metabolism by hydrolyzing fatty acid ethyl esters which are produced in the body in response to alcohol consumption (Heier et al., 2016) .
Genetic as well as pharmacological inactivation of MGL in mice causes a strong increase of MGs in many tissues including brain, liver, adipose tissue, intestine, and others, demonstrating a major role of the enzyme in MG catabolism (Chanda et al., 2010; Long, Weiwei, et al., 2009; Schlosburg et al., 2010) . Accordingly, MGL is expressed in many cell types of various tissues. In mice, highest expression is observed in brown and white adipose tissue (Karlsson et al., 1997) and the brain (Dinh et al., 2002) . MGL is expressed throughout the major cell types of the brain, including neurons, astrocytes, oligodendrocytes, and to a lower extent in microglia (Dinh et al., 2002; Stella, 2004) . Several studies demonstrated the existence of MGL proteins with different molecular weight by Western Blot analysis. In murine adipose tissue, liver, heart, lung, spleen, kidney, and adrenal glands, a single MGL band is observed at 33 kDa, whereas in skeletal muscle, MGL can be detected at 40 kDa. In testis, MGL is found at 30 kDa, and in the brain even two bands are observed at 33 and 35 kDa (Blankman et al., 2007; Karlsson et al., 2001 ). Although it is not fully understood how these variations occur, they very likely derive from differential use of start codons in the 5′ leader sequence of the Mgll gene as well as alternative splicing (Karlsson et al., 2001) . The existence of different splice variants might also explain the variation in the subcellular localization of MGL. For human Mgll, splice variants have been described that lack exon 5 which encodes for the cap region which is implicated in substrate selectivity and membrane localization (Bertrand et al., 2010; Labar, Bauvois, et al., 2010; Scalvini, Piomelli, & Mor, 2016) . Surprisingly, little is known about the regulation of MGL. At the transcriptional level, microarray analysis of murine liver revealed that MGL expression is regulated via the transcription factor peroxisome proliferator activated receptor α (PPARα) (Rakhshandehroo et al., 2007) . PPARs are nuclear receptors that heterodimerize with retinoid et al. (2015) X receptor upon ligand binding and thereby activate transcription of genes, most of which are involved in energy metabolism (GrygielGórniak, 2014) . In wild-type mice, PPARα agonist treatment led to a 6-fold increase in Mgll gene expression, a response that was absent in PPARα-deficient mice (Rakhshandehroo et al., 2007) . Furthermore, Chon et al. demonstrated that intestinal and hepatic MGL protein levels are induced in mice upon feeding a diet that contains a high amount of fat, indicating nutritional regulation of MGL expression (Chon, Zhou, Dixon, & Storch, 2007) . At the posttranslational level, recent data suggest that MGL activity is regulated via sulfenylation of cysteine residues by H 2 O 2 . The involved cysteines are located in the cap region that controls entry of the substrate into the active site of the enzyme. H 2 O 2 exposure leads to a rapid, reversible, non-competitive inhibition of MGL activity. This inhibition may be relevant under conditions associated with increased oxidative stress such as brain ischemia in which increased 2-AG levels may have protective effects (Dotsey et al., 2015) .
Other MG hydrolases
Although MGL is clearly the major enzyme in MG catabolism in most tissues, other MG hydrolases may contribute to this process in cell types or cellular compartments that do not contain MGL. HSL was the first intracellular enzyme characterized with MG hydrolase activity (Fredrikson, Tornqvist, & Belfrage, 1986; Yeaman, 1990 ). This enzyme is highly expressed in adipose tissue and plays an important role in the mobilization of fatty acids from TG stores. Yet, HSL has substantial MG hydrolase activity and can therefore partially compensate MGL deficiency in lipolysis (Taschler et al., 2011) . Fatty acid amide hydrolase (FAAH), responsible for the degradation of the EC arachidonoyl ethanolamine (AEA, anandamide), was also shown to hydrolyze 2-AG in vitro (Goparaju, Ueda, Yamaguchi, & Yamamoto, 1998) . However, FAAH-deficient mice have unaltered 2-AG levels, questioning a physiological role of FAAH as a MG hydrolase in vivo (Cravatt et al., 2001) . In 2007, α/β hydrolase domains containing protein 6 and 12 (ABHD6 and ABHD12) were identified as additional MG hydrolases in the brain, accounting for about 15% of total membrane activity (Blankman et al., 2007) . Recent reports suggest that ABHD12 is involved in phospholipid rather than MG metabolism. ABHD12 acts as a potent lyso-phosphatidyl serine hydrolase, and human ABHD12 mutations or genetic deletion in mice are associated with the neurodegenerative disease PHARC (polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract disease) (Blankman, Long, Trauger, Siuzdak, & Cravatt, 2013; Fiskerstrand et al., 2010) . ABHD6 was proposed to acts as the major 2-AG hydrolase in cell types in which MGL is not expressed (Alhouayek, Masquelier, Cani, Lambert, & Muccioli, 2013; Marrs et al., 2010) . Nevertheless, MG hydrolase activity of ABHD6 may also play a role in cells expressing MGL, via distinct cellular distribution of both enzymes. In neurons, for instance, ABHD6 is localized at postsynaptic membranes while MGL is predominantly found presynaptically. Accordingly, ABHD6 may counteract 2-AG formation at the post-synaptic site (Marrs et al., 2010) . Moreover, recent evidence suggests that ABHD6 plays a role in the hydrolysis of MGs esterified in sn-1 position, especially 1-palmitoyl glycerol and 1-stearoyl glycerol. Zhao et al. suggested that these saturated MG species activate Munc13-1 that is required for the priming of insulin containing vesicles, thereby promoting exocytosis of insulin in pancreatic β-cells (Zhao et al., 2014 (Zhao et al., , 2015 . Conversely, inhibition of MGL decreases glucose-stimulated insulin secretion in INS-1 cells and rat islets (Berdan, Erion, Burritt, Corkey, & Deeney, 2016) . In contrast to MGL, ABHD6 can also hydrolyze acidic lysophospholipids and the late endosomal/lysosomal lipid bis(monoacylglycero)phosphate (Pribasnig et al., 2015; Thomas et al., 2013) . The enzyme co-localizes with acidic organelles and might be therefore involved in the remodeling of outer membranes of these organelles (Pribasnig et al., 2015) . Recently, another member of the ABHD family, namely ABHD2, was identified as a 2-AG hydrolase in spermatozoa. This highly interesting study suggests that ABHD2 is directly activated by progesterone and responsible for the genome-independent action of the hormone via 2-AG signaling (Miller et al., 2016) . This observation implicates that lipid-metabolizing enzymes can represent direct targets of hormones. Besides ABHD family members, triglyceride hydrolase 2, rat esterase 4 and 10, carboxyl esterase 1, and neuropathy target esterase have been shown to hydrolyze MG in vitro (Lehner & Vance, 1999; van Tienhoven, Atkins, Li, & Glynn, 2002; Xie et al., 2010) . While all these hydrolases are active at neutral pH, lysosomal acid lipase was reported to hydrolyze MG in acidic organelles (Sheriff, Du, & Grabowski, 1995) .
MGL in endocannabinoid signaling
After initial characterization, MGL returned into the spotlight of research when Dinh et al. demonstrated that MGL is the primary enzyme in the brain hydrolyzing 2-AG. This MG species belongs to a class of signaling lipids called ECs which are primarily derivatives of AA. In general, it is thought that Δ 9 -tetrahydrocannabinol (Δ 9 -THC), the major psychoactive component of Cannabis sativa (Gaoni & Mechoulam, 1964) , mimics the action of ECs. Δ 9 -THC, synthetic cannabinoids, and ECs bind and activate cannabinoid (CB) receptors of which two have been characterized. The CB 1 receptor is expressed mainly in central and peripheral neurons (Howlett et al., 1990) , but also various other cell types including adipocytes and hepatocytes (Pagotto, Marsicano, Cota, Lutz, & Pasquali, 2006) . Its activation is involved in the regulation of various physiological processes including appetite, activity, emotions, pain processing, and energy homeostasis (de Kloet & Woods, 2009; Hasenoehrl, Taschler, Storr, & Schicho, 2016; Maccarrone, Bernardi, Agrò, & Centonze, 2011; Silvestri & Di Marzo, 2013) . The CB 2 receptor is predominantly expressed in cells of the hematopoietic system and important in the regulation of immune response (Galiègue et al., 1995; Munro, Thomas, & Abu-Shaar, 1993) . Besides 2-AG, AEA acts as an EC, however its tissue abundance is more than 100 times lower in the brain as compared to 2-AG (Bisogno, Berrendero, et al., 1999) . Generally, ECs are produced "on demand" and are rapidly degraded by intracellular enzymes after receptor binding. ECs, together with the two receptors and the EC metabolizing enzymes, constitute the EC system. CB receptors mainly signal through G i/o proteins, inhibit voltage gated Ca 2+ channels and activate A-type and inwardly rectifying K + currents (Howlett, 2005 (Okamoto, Morishita, Tsuboi, Tonai, & Ueda, 2004) , or alternatively by the phospholipase ABHD4 and glycerophospho-diesterase 1 (Simon & Cravatt, 2008) . AEA and other N-acyl ethanolamines are hydrolyzed by FAAH (Cravatt et al., 2001; Deutsch, Ueda, & Yamamoto, 2002) . AEA synthesis and degradation pathways are reviewed in detail elsewhere (Cascio & Marini, 2015) . 2-AG is synthesized by the consecutive action of a PLC generating 2-arachidonoyl DG which is further hydrolyzed by sn-1 specific DAGLs. Very recently, DDH domain containing 2 has been shown to possess DG hydrolase activity and its overexpression in CHO cells results in an increased generation of 2-AG (Araki et al., 2016) . 2-AG may undergo different metabolic pathways resulting in inactivation or in the generation of other signaling molecules. The strong increase in 2-AG levels in MGLknockout (ko) mice implicates that most of the EC is degraded by hydrolysis. However, 2-AG can be phosphorylated to lyso-phosphatidic acid by MG kinase(s) (Simpson, Itabe, Reynolds, King, & Glomset, 1991) and metabolized by cyclooxygenase-2 (COX-2) resulting in the formation of prostaglandin glycerol esters (Gopez et al., 2005; Telleria-Diaz et al., 2010) . Alternatively, 2-AG may be acylated by acyltransferases to generate DG (Cao, Cheng, & Shi, 2007; Cao, Lockwood, Burn, & Shi, 2003; Yen, Farese, & Farese, 2003; Yen et al., 2002) . A schematic overview of 2-AG synthesis and degradation is illustrated in Fig. 2. 
MGL blockade and CB receptor desensitization
Within recent years, different strategies have been established to investigate the physiological role of MGL in vivo. Several MGL inhibitors have been synthetized that block MGL activity, as reviewed extensively elsewhere (Kohnz & Nomura, 2014; Labar, Wouters and Lambert, 2010) (Table 1) , and different genetically modified mouse models have been generated (Table 2) . One of the first selective inhibitors developed was JZL184 which inhibits MGL by irreversible active site carbamylation (Long, Weiwei, et al., 2009 ). JZL184 inhibits around 90% of 2-AG hydrolase activity in the brain and leads to strong accumulation of 2-AG and other MGs 30 min after administration (Long, Weiwei, et al., 2009 ). However, MGs did not increase in all tissues which could either indicate that MGL activity is compensated by other MG hydrolases in certain tissues or that JZL184 shows a tissue-specific distribution pattern and MGL is not fully inhibited in all tissues (Long, Nomura, & Cravatt, 2009) .
The in vivo effects of MGL inhibitors have been investigated using the "tetrad test for cannabinoid activity" which consists of four individual tests: analgesia, sedation, catalepsy, and hypothermia (Wiley & Martin, 2003) . Acute blockade of MGL induces analgesia, hypomotility, and hypothermia, while catalepsy was not observed (Long, Weiwei, et al., 2009 ). The effects of JZL184 are dependent on CB 1 receptor activation since they were absent in CB 1 receptor-deficient (CB 1 -ko) mice. None of the MGL inhibitors developed so far produced catalepsy which might require the inhibition of both MGL and FAAH as shown with the dual inhibitor JZL195 (Long, Nomura, Vann, et al., 2009 ). However, these results clearly demonstrate that CB 1 receptor agonists and MGL inhibitors have similar effects in vivo.
As mentioned above, MGL-ko mice exhibit dramatically increased 2-AG levels in the brain and in peripheral tissues. Notably, increased 2-AG levels do not evoke cannabimimetic effects in these mice as observed in response to acute inhibitor treatment. The reason for this discrepancy is that chronically elevated 2-AG in MGL-ko mice causes desensitization of CB 1 receptors in the brain similar to what may occur in response to chronic, heavy cannabis abuse (Borgelt, Franson, Nussbaum, & Wang, 2013; González, Cebeira, & Fernández-Ruiz, 2005 ). Accordingly, MGL-deficiency is associated with decreased CB 1 receptor density, reduced CB 1 receptor ligand binding (Chanda et al., 2010; Schlosburg et al., 2010) , and resistance to the hypometabolic effects of CB receptor agonists (Taschler et al., 2011) . A recent study suggests that chronically increased 2-AG induced basal CB 1 receptor/G i/o signaling in the brain but dampened agonist-evoked responses (Navia-Paldanius et al., 2015) . Impaired CB 1 receptor signaling due to desensitization in the brain is accompanied by increased β-arrestin 2 binding and a significant reduction of ERK1/2 phosphorylation in different brain regions, such as the amygdala, medial prefrontal cortex, and hippocampus (CA1 and CA3), but not in the cerebellum (Imperatore et al., 2015) . Interestingly, β-arrestin2 mediated CB 1 receptor desensitization was observed in brain areas controlling emotional and stress related states, pain sensation, memory and learning, whereas brain areas associated with motor function were not affected by desensitization. Receptor internalization/desensitization is a process generally observed for G-protein coupled receptors, and the CB 1 receptor was shown to internalize only minutes after receptor activation in cell culture (Hsieh, Brown, Derleth, & Mackie, 1999) . Recently, also desensitization of peripherally expressed CB 1 receptors in the enteric nervous system has been demonstrated by chronic pharmacological inhibition or genetic deletion of MGL. While MGL-ko mice show normal gut motility under physiological conditions, they are insensitive to CB receptor agonist-induced intestinal hypomotility (Taschler et al., 2015) . Whether CB 1 receptor activity/ Fig. 2 . Monoglyceride lipase in 2-arachidonoyl glycerol signaling and arachidonic acid metabolism. 2-AG is generated by hydrolysis of membrane phospholipids (PL) to diglycerides (DGs) by phospholipase C (PLC) and subsequent hydrolysis by diglyceride lipase (DAGL). 2-AG is secreted and binds to CB 1 receptors (CB 1 R), CB 2 receptors (CB 2 R), or other yet uncharacterized receptors. 2-AG is then metabolized by oxidation through cyclooxygenase 2 (COX-2) generating prostaglandin-glyceryl esters (PG-GE) or acylation through monoacylglycerol acyltransferase (MGAT) to DG. The majority of 2-AG is hydrolyzed by monoglyceride lipase (MGL) to glycerol and arachidonic acid (AA). AA is either re-esterified into cellular neutral lipid (NL) or PLs or conducted to β-oxidation to generate acetyl-CoA. AA can also be subjected to oxidation by COX-1, COX-2, lipoxygenases (LOX), or cytochrome p450 (CYP) generating important signaling lipids like prostaglandins, hydroxyeicosatetraenoic acid/epoxy-eicosatrienoic acid (HETE, EET), and hydroperoxyeicosatetraenoic acid (HPETE).
expression is impaired in other peripheral tissues and non-neuronal cells remains elusive.
In contrast to the CB 1 receptor, data on CB 2 receptor desensitization/ internalization are scarce. Previous reports suggest that CB 2 receptors are not desensitized in MGL-ko mice. Chanda et al. showed by CB receptor agonist binding studies that CB 2 receptor density is unaltered in the spleen, however, a functional characterization of the receptor activity was not performed (Chanda et al., 2010) . In a more recent study, Vujic et al. suggest that CB 2 receptors are not desensitized in MGL-ko macrophages isolated from mice on an ApoE-deficient background. These conclusions are based on Ca 2+ -flux experiments in response to 2-AG stimulation (Vujic et al., 2016 ). Yet, cell culture experiments show that CB 2 receptors undergo internalization after activation (Grimsey, Goodfellow, Dragunow, & Glass, 2011) . Since 2-AG is a physiologically relevant agonist of CB 2 receptors, it is reasonable to assume that also these receptors desensitize in MGL-ko mice. Thus, careful evaluation of inhibitor concentrations may be the key to avoid CB receptor desensitization upon MGL inhibition. Indeed, while the injection of JZL184 at concentrations of 8 mg/kg mouse and higher over a period of 5 days causes CB 1 receptor desensitization (Schlosburg et al., 2010) , similar to observations in MGL-ko mice, the injection of 4 mg/kg did not promote CB 1 receptor desensitization in mice (Kinsey et al., 2013) . Burston et al. investigated the effects of acute and chronic MGL inhibition in a rat model of osteoarthritis. Repeated administration of MJN110 at high doses (5 mg/kg) resulted in anti-nociceptive tolerance whereas lower concentrations (1 mg/kg) preserved antinociception (Burston et al., 2016) . Despite CB 1 receptor desensitization caused by chronic MGL inhibition, blockade of the enzyme has still protective effects in a variety of pathophysiological states such as inflammation and neurodegeneration, mostly via CB 1 receptor independent mechanisms as discussed in the following section (Grabner et al., 2016; Nomura, Morrison, et al., 2011; Viader et al., 2015) .
MGL in inflammation and pain
Cannabinoids have a long history as analgesics (Mechoulam & Parker, 2013; Touw, 1981) and research of the last decades suggests close connections between the EC system and inflammation (Turcotte, Chouinard, Lefebvre, & Flamand, 2015) . MGL is a highly interesting target for the treatment of inflammation since it conversely regulates 2-AG and AA levels in several tissues (Dinh et al., 2002; Long, Weiwei, et al., 2009) . Accordingly, MGL deficiency exerts a dual anti-inflammatory function. First, MGL ablation leads to augmented 2-AG levels, leading to increased CB receptor activation. Activation of CB 1 or CB 2 receptors by endogenous or exogenous agonists has been shown to have beneficial effects on various diseases harboring an inflammatory component (Klein, 2005; Turcotte et al., 2015) . Second, MGL limits AA availability causing CB receptor independent anti-inflammatory effects in the brain and some peripheral tissues (Fig. 2) . Notably, cytosolic PLA2 (cPLA2) has been considered as mainly responsible for mobilizing AA for prostaglandin synthesis in the brain (Buczynski, Dumlao, & Dennis, 2009 ). Yet, cPLA2-deficient mice do not show a reduction in brain free AA levels indicating that other enzymes mediate this process (Rosenberger, Villacreses, Contreras, Bonventre, & Rapoport, 2003) . Upon characterization of mice treated with the MGL inhibitor JZL184, a significant and dose dependent reduction in brain AA was observed (Long, Weiwei, et al., 2009 ). This effect was also confirmed in MGLdeficient mice (Chanda et al., 2010; Schlosburg et al., 2010) . Further, it was demonstrated that global genetic deletion or pharmacological inhibition of MGL protects mice from LPS-induced neuroinflammation independent of CB receptor activation, due to reduced AA availability for prostaglandin synthesis (Nomura, Morrison, et al., 2011) . Diminished prostaglandin levels attenuate cytokine production and microglia activation (Nomura, Morrison, et al., 2011) . Since then, numerous studies demonstrated beneficial effects of MGL ablation on various disease models harboring an inflammatory component. These effects are mediated by CB receptor dependent and/or independent effects. MGL inhibition improves pathologies of Parkinson's (Nomura, Morrison, et al., 2011 ) and Alzheimer's disease (Chen et al., 2012; Piro et al., 2012) , multiple sclerosis (Hernández-Torres et al., 2014; Pryce et al., 2013) , and Down syndrome (Lysenko et al., 2014) . Interestingly, MGL in neurons and astrocytes equally contributes to brain AA availability upon inflammatory stimuli, while MGL in microglia plays a minor role (Grabner et al., 2016; Viader et al., 2015) . In peripheral tissues, MGL inhibition leads to attenuated liver (Cao et al., 2013) , lung (Costola-de-Souza et al., 2013) , and muscle injury (Jiang et al., 2015) . MGL deficiency also extenuates colitis and related systemic inflammation (Alhouayek, Lambert, Delzenne, Cani, & Muccioli, 2011) .
Pharmacological inhibition of MGL thus represents a highly interesting strategy to treat inflammation. To date, the majority of antiinflammatory drugs used are COX inhibitors, prescribed in many of the aforementioned diseases. As an example, pharmacological inhibition or genetic deletion of COX-1 has beneficial effects on neuroinflammation and neurodegenerative disorders (Choi & Bosetti, 2009; Choi, Langenbach, & Bosetti, 2008; Vlad, Miller, Kowall, & Felson, 2008) . A severe drawback of COX inhibitors however is that they cause gastrointestinal (GI) injury (Ng & Chan, 2010; Singh, 1998) . Side effects of selective COX-2 inhibitors (coxibs) are less severe in the GI tract, however, wide usage of these drugs is restricted owing to cardiovascular complications (Cannon & Cannon, 2012) . Inhibition of MGL could thus represent an anti-inflammatory strategy, which avoids adverse effects of COX inhibition. The beneficial effects of MGL ablation are thereby comparable to those of COX inhibitors, however, MGL inhibition by JZL184 does not lead to GI injury, but protects from COX-1 inhibitor induced GI damage (Kinsey, Nomura, et al., 2011) . Recently, a Phase 1b study has been initiated to evaluate the effects of a single dose of the orally active human MGL inhibitor ABX-1431 (ABIDE Therapeutics) for the treatment of functional dyspepsia.
Cannabinoids and (naturally occurring) COX inhibitors have a long common history, likely being the first analgesics used by humans. To date, it is well established that CB receptor agonists exhibit analgesic effects (Fine & Rosenfeld, 2013; Manzanares, Julian, & Carrascosa, 2006) . Concordantly, pharmacological MGL inhibition leads to antinociceptive effects in various models of pain, including inflammatory, neuropathic, thermal, and chemically induced pain in a 2-AG/CB 1 receptor dependent manner (Ghosh et al., 2013; Griebel et al., 2015; Guindon, Guijarro, Piomelli, & Hohmann, 2011; Kinsey et al., 2009; Long, Weiwei, et al., 2009; Woodhams et al., 2012) . The orally active MGL inhibitor SAR127303 has been reported to have anti-nociceptive properties, and it was shown that even repeated administration caused no tolerance since the effects were maintained in the formalin test. However, the authors also demonstrated that inhibition of MGL impaired memory performance (Griebel et al., 2015) . Interestingly, administration of the highly selective MGL inhibitor KML29 produces analgesia without cannabimimetic side effects, its chronic administration, however, leads to CB 1 receptor desensitization, as similarly observed for other MGL inhibitors (Ignatowska-Jankowska et al., 2014) . Also, genetic mouse models of MGL deficiency, do not show analgesic properties due to constantly increased 2-AG levels and subsequent CB 1 receptor desensitization (Chanda et al., 2010; Schlosburg et al., 2010) , as mentioned previously. Nevertheless, by combining anti-inflammatory and antinociceptive properties, MGL inhibitors may represent a promising strategy to counteract inflammation and pain.
MGL in metabolic disorders
Metabolic syndrome is a major public health care concern and combines several pathological conditions, including abdominal obesity, elevated blood pressure, insulin resistance and high blood glucose, high serum TG and low high-density lipoprotein levels. It is closely associated with the risk to develop type 2 diabetes and cardiovascular disease. A large number of studies implicates that metabolic disorders are associated with the EC system. In general, activation of CB 1 receptors is associated with increased lipid deposition, increased lipogenesis, hyperphagy, and hypomotility as recently reviewed (Quarta, Mazza, Obici, Pasquali, & Pagotto, 2011) . In line, acute treatment of mice with isopropyl dodecylfluorophosphonate (IDFP), an inhibitor of MGL and FAAH, caused hepatic steatosis and impaired glucose tolerance by CB 1 receptor dependent and independent mechanisms (Ruby et al., 2011) . Moreover, a single administration of JZL184 (40 mg/kg) significantly increased food intake (Woodhams et al., 2012) . In contrast, CB 1 -ko mice are resistant to diet induced obesity, hepatic steatosis and insulin resistance. These effects are mostly caused by reduced caloric intake and increased energy expenditure (Cota et al., 2003; Quarta et al., 2010) . Similarly, CB 1 receptor blockade with rimonabant (Acomplia®), a selective inverse CB 1 receptor agonist (Rinaldi-Carmona et al., 1994) , ameliorates hepatic steatosis and dyslipidemia in obese mice and rats (Gary-Bobo et al., 2007; Osei-Hyiaman et al., 2008; Tam et al., 2010) . Important evidence was provided by studies in obese and diabetic patients treated with rimonabant. The drug promoted weight loss and improved cardiovascular risk factors (Scheen et al., 2006; Van Gaal et al., 2005 ). Yet, rimonabant was withdrawn from the market due to serious sideeffects such as depression and even suicidal tendencies (Christensen, Kristensen, Bartels, Bliddal, & Astrup, 2007) . Based on these observations, it can be assumed that inactivation of MGL increases EC signaling, promoting obesity and co-morbidities. Yet, MGL-ko mice are lean and show no alterations in plasma lipid parameters in the fed state while fasted animals exhibit reduced plasma glycerol and TG levels. Moreover, MGL-deficiency protects from high fat diet (HFD) induced insulin resistance despite similar weight gain (Taschler et al., 2011) . A more recent study suggests that MGL-ko mice exhibit decreased body weight and fat mass upon HFD feeding (Douglass et al., 2015) . It is important to mention that the fat rich diets used in both studies vary in fat content (55% vs 25% fat w/w), possibly explaining the discrepancy in diet induced obesity. Also, Douglass et al. demonstrated even higher differences in body fat mass when using a diet with low fat content (4.3% w/w) (Douglass et al., 2015) . Together, these observations suggest that the metabolic effects of MGL inactivation cannot be explained by hyperactivation of the EC system. As mentioned above, MGL is involved in TG hydrolysis in adipocytes, and reduced lipolysis is known to counteract the development of insulin resistance (Boden, 2011) . Furthermore, MGL inactivation has anti-inflammatory effects and insulin resistance is associated with inflammation in insulin-sensitive tissues (Samuel & Shulman, 2012) . Finally, MGL inactivation can affect lipid signaling independent of CB receptors. 2-oleoyl glycerol (2-OG) has been identified as a ligand of the G-protein coupled receptor GPR119. Activation of this receptor stimulates the intestinal release of incretin hormones, like glucagon-like peptide-1 (GLP-1), having well-known beneficial effects in the development and progression of diabetic complications (Hansen et al., 2011) . Important effects of GLP-1 are augmentation of insulin secretion and inhibition of glucagon release. Yet, MGL has also been directly implicated in the regulation of insulin release in pancreatic β-cells. A recently published study suggests that MGL inactivation inhibits glucose-stimulated and depolarization-induced insulin secretion (Berdan et al., 2016) . Thus, in addition to changes in EC signaling, MGL inactivation may have complex effects on metabolic disorders by affecting lipolysis, inflammation, incretin and insulin signaling.
Evidence for an important role of MGL in energy homeostasis comes also from animal models overexpressing the enzyme. Transgenic mice that overexpress MGL in the intestine develop obesity and liver steatosis already after three weeks of HFD feeding, caused by decreased energy expenditure and hyperphagia. The authors speculated that 2-AG might act as a satiety signal (Chon et al., 2012) . In contrast, other studies demonstrate that 2-AG in the intestine is increased upon fat intake and acts as hunger signal which is abandoned upon local CB 1 receptor antagonism or surgical transection of the vagus nerve (DiPatrizio, Astarita, Schwartz, Li, & Piomelli, 2011). Interestingly, this effect seems to depend on distinct fatty acids (DiPatrizio, Joslin, Jung, & Piomelli, 2013) . Another study demonstrated that MGL, expressed in the central nervous system (CNS), is able to influence peripheral energy balance (Jung et al., 2012) . Transgenic mice overexpressing MGL specifically in the forebrain are resistant to HFD-induced obesity mostly via elevated brown adipose tissue thermogenesis. Interestingly, these mice maintained leanness and insulin sensitivity despite increased food intake and decreased locomotor activity (Jung et al., 2012) . Thus, MGL overexpression has different effects on energy homeostasis depending on the site of expression.
EC signaling has also been implicated in the pathogenesis of atherosclerosis. Initially, it was observed that low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice (Steffens et al., 2005) . The beneficial effects of Δ 9 -THC were completely blocked by a selective CB 2 receptor antagonist, implicating that CB 2 receptors located on immune cells play a central role in this process. Subsequent studies showed that rimonabant has anti-atherosclerotic effects in low density lipoprotein (LDL) receptor-deficient mice (Dol-Gleizes et al., 2008) . These effects are due to an enhancement of reverse cholesterol transport (Sugamura et al., 2010 ). Yet, clinical trials with rimonabant did not show any significant benefit of this agent in preventing progression of atherosclerosis (Nissen et al., 2008) . A recent study investigated atherosclerosis-susceptibility of MGL/ApoE double ko mice. Mice exhibited a body weight gain and plasma lipoprotein profile similar to their wild-type littermates. However, these MGL-ko/ApoE-ko mice displayed larger lesion size and changes in plaque composition indicating increased plaque stability (Vujic et al., 2016) . Treatment with a CB 2 receptor inverse agonist prevented these changes suggesting that MGL inactivation provokes increased CB 2 receptor signaling.
Together, all these studies emphasize an important role for MGL in the regulation of energy homeostasis. Acute blockade of MGL induces hyperphagy, while long-term blockade of MGL attenuates diet induced obesity and insulin resistance. Therefore, the potential of MGL inhibitors as therapeutic strategy to treat obesity has to be evaluated carefully. The effects of MGL inhibition cannot be limited to changes in EC signaling. Further studies are required to outline MGL's role in the regulation of incretin/insulin secretion and inflammation in insulin-sensitive tissues. Nevertheless, inhibition of MGL might represent an interesting therapeutic option for the treatment of metabolic disease.
MGL in stress, emotion, and addiction
EC effects on neuronal transmission have a deep impact on stress response, mood, and emotion (Hill & Gorzalka, 2009; Lutz, 2009) . Activation of CB 1 receptors leads to anxiolysis and improves mood and depression like behavior in humans and animal models (Berrendero & Maldonado, 2002; Denson & Earleywine, 2006; Patel & Hillard, 2006) . Conversely, administration of the CB 1 receptor inverse agonist rimonabant leads to increased anxiety and depression in humans (Samat, Tomlinson, Taheri, & Thomas, 2008) . The impact of (endo-)cannabinoid signaling on acute and chronic stress (Hillard, 2014; Morena, Patel, Bains, & Hill, 2015; Riebe & Wotjak, 2011 ), emotion (McLaughlin & Gobbi, 2012 , mood and depression (Gaetani et al., 2009; Micale, Di Marzo, Sulcova, Wotjak, & Drago, 2013) have been extensively reviewed recently, thus we only briefly summarize the role of MGL therein. MGL inhibition by JZL184 exhibits beneficial effects in various behavioral tests of anxiety via elevated 2-AG levels and activation of CB 1 receptors (Aliczki, Balogh, Tulogdi, & Haller, 2012; Aliczki et al., 2013; Busquets-Garcia et al., 2011; Kinsey, O'Neal, Long, Cravatt, & Lichtman, 2011; Lomazzo et al., 2015; Sumislawski, Ramikie, & Patel, 2011) , but impairs short-term fear extinction in mice (Hartley et al., 2016) . Reduction of 2-AG levels by genetic deletion of DAGLα leads to increased anxiety which is ameliorated upon restoration by pharmacological MGL inhibition (Shonesy et al., 2014) . JZL184 treatment also improves chronic stress-induced depression-like behavior (Zhong et al., 2014) and attenuates plasma corticosterone levels in the early recovery from restraint stress (Roberts, Stuhr, Hutz, Raff, & Hillard, 2014).
Conversely, CB 1 receptor desensitization in MGL-deficient mice leads to anxiety-like behavior (Imperatore et al., 2015) . Impaired CB 1 receptor signaling could thus be a major drawback of 2-AG elevation by chronic MGL inhibition, as discussed above.
Another pharmacologically highly relevant area of EC action is drug abuse and withdrawal. ECs play a major role in regulating addictive behavior, and their involvement in opioid, nicotine, and alcohol dependence has been extensively investigated (Parolaro, Vigano, Realini, & Rubino, 2007; Scavone, Sterling, & Van Bockstaele, 2013) . Although it has long been known that Cannabis sativa ameliorates opioid withdrawal symptoms (Birch, 1889 ), MGL's particular role therein has been investigated in detail just recently. Several studies demonstrated that the MGL inhibitor JZL184 attenuates Δ 9 -THC (Schlosburg et al., 2009) , nicotine (Muldoon et al., 2015) , and opioid (Ramesh et al., 2011 (Ramesh et al., , 2013 withdrawal in mice, but does not improve aversive behavioral aspects of withdrawal (Gamage et al., 2015) . Taken together, pharmacological inhibition of MGL represents a promising strategy to ameliorate stress, depression, and drug withdrawal symptoms.
MGL in cancer
First evidence for a pathophysiological role of MGL in cancer emerged when Nomura et al. demonstrated that MGL was highly elevated in aggressive ovarian, breast and melanoma cancer cells. The enzyme was involved in cellular growth and survival, in vitro migration, and invasion of these cells . The study suggests that MGL affects tumor growth through involvement of a pool of fatty acids that promotes pathogenicity, and that blockade of MGL reduces this pool leading to decreased cancer cell aggressiveness independently of EC signaling and CB receptor activation . Interestingly, several MGL-derived bioactive lipid mediators affecting tumor invasiveness were identified in this study, including lysophosphatidic acid and prostaglandin E2. Both lipids are known to promote cancer aggressiveness (O'Callaghan & Houston, 2015; Tsujiuchi, Araki, Hirane, Dong, & Fukushima, 2014) , and their supplementation reestablished malignancy of MGL deficient cancer cells . In a subsequent study, the group further demonstrated that MGL activity was also high in aggressive prostate cancer cells and that anti-tumorigenic EC signaling was terminated by MGL via free fatty acid reduction and by CB 1 receptor activation (Nomura, Lombardi, et al., 2011) . High MGL expression was also detected in nasopharyngeal (Hu et al., 2014) and hepatocellular carcinoma (Zhang et al., 2016; Zhu et al., 2016) . Knockdown of MGL inhibited migration of these cells further indicating a tumor-promoting role of MGL. This may also apply for neuroblastoma cells because inhibition of MGL and type II topoisomerase also decreased proliferation (Matuszak et al., 2012) .
In contrast, the role of MGL in the oncogenesis of colorectal cancer is controversial. In line with the previous data, Ye et al. demonstrated high expression of MGL in colorectal cancerous tissues and a tumorpromoting effect of MGL in colorectal cancer cell lines (Ye et al., 2011) . Conversely, Sun et al. described reduced MGL expression in colorectal tumor tissues (and also other human malignancies) and a colony formation suppressive effect in MGL overexpressing colon cancer cells (Sun et al., 2013) . The authors of this study suggested that the underlying mechanism by which MGL may affect tumor growth could be through constitutive suppression of Akt phosphorylation because shRNA mediated knockdown of MGL expression enhanced phosphorylation of Akt in both HT29 colon cancer and MDA-MB-231 breast cancer cells (Sun et al., 2013) . The discrepancy between these studies is unclear and requires further research on the role of MGL in colorectal cancer.
Taken together, studies in various cancer cell lines suggest that MGL may drive cancer malignancy. However, the picture may be different in colon cancer in which a tumor suppressive role for MGL was proposed. Certainly, more research is needed to define the role of MGL in human malignancies and whether MGL's role involves CB receptor dependent or independent mechanisms.
Conclusions and outlook
Starting from the first description of MGL activity more than 50 years ago, MGL research has shifted from fat breakdown to endocannabinoid signaling and further to AA metabolism. Apparently, MGL has a central function in feeding AA into COX and LOX pathways. The investigation of these pathways will be of paramount importance to understand the role of MGL in various diseases. Accordingly, the pharmacological inhibition of MGL evokes two different effects: First, levels of the EC 2-AG rise, inducing anti-inflammatory and analgesic effects via activation of CB 1 and CB 2 receptors and, second, the pool of AA is lowered counteracting the synthesis of prostaglandins. Based on these mechanisms, MGL inhibitors represent an alternative to COX inhibitors in the treatment of inflammation and pain.
Yet, it has to be considered that the EC system has a major impact on neuronal signaling and, consequently, CB receptor activation or desensitization upon MGL inhibition may result in adverse psychological effects. Peripherally restricted MGL inhibitors may circumvent this issue. Nevertheless, MGL inhibitors may prove useful in pathologies where moderate adverse effects are acceptable. Studies in various disease models, such as intestinal inflammation, hepatic injury, endotoxemia, insulin resistance, depression and stress, opioid and nicotine withdrawal already suggest that inhibition of MGL may be a powerful antiinflammatory pharmacological strategy. In addition, MGL inhibitors may have high potential as anticancer drugs, however, studies on the role of MGL in cancer are conflicting and the role of MGL in the metabolism of cancers cells is incompletely understood. Furthermore, it should be kept in mind that MGL not only degrades 2-AG but also other 2-MGs esterified with PUFAs and thus may affect the mobilization of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA). These PUFAs are precursors of potent inflammation-resolving mediators such as resolvins and protectins. From preclinical studies we have to assume that therapy with MGL inhibitors may cause CB 1 receptor desensitization in long term use which hampers therapeutic success. This obstacle might be overcome by assessing the lowest effective dose avoiding CB 1 receptor desensitization. In conclusion, the therapeutic potential of MGL inhibition is vast and promising, but warrants further research. Since highly selective inhibitors targeting human MGL have been developed, studies in the near future will disclose whether MGL inhibitors can become an alternative to COX inhibitors in the treatment of inflammation, pain, and other disorders.
Conflict of interest statement
The authors declare that there are no conflicts of interest.
